Cargando…
Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs
BACKGROUND: Agency is a pervasive feature of the health care market, with doctors acting as agents for both patients and the health care system. In a context of scarce resources, doctors are required to take opportunity cost into account when prescribing treatments, while cost containment policies c...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646475/ https://www.ncbi.nlm.nih.gov/pubmed/26635482 http://dx.doi.org/10.2147/CEOR.S88531 |
_version_ | 1782400941999259648 |
---|---|
author | Menditto, Enrica Orlando, Valentina Coretti, Silvia Putignano, Daria Fiorentino, Denise Ruggeri, Matteo |
author_facet | Menditto, Enrica Orlando, Valentina Coretti, Silvia Putignano, Daria Fiorentino, Denise Ruggeri, Matteo |
author_sort | Menditto, Enrica |
collection | PubMed |
description | BACKGROUND: Agency is a pervasive feature of the health care market, with doctors acting as agents for both patients and the health care system. In a context of scarce resources, doctors are required to take opportunity cost into account when prescribing treatments, while cost containment policies cannot overlook their active role in determining health care resource allocation. This paper addresses this issue, investigating the effects of cost containment measures in the market of biosimilar drugs that represent a viable and cost-saving strategy for the reduction of health care expenditure. The analysis focuses on a particular region in Italy, where several timely policies to incentivize biosimilar prescribing were launched. METHODS: Drugs were identified by the anatomical therapeutic chemical classification system. Information about biosimilar drugs and their originator biological products was extracted from the IMS Health regional database. Drug consumption was expressed in terms of counting units, while expenditure was evaluated in Euro (€). The market penetration of biosimilars was analyzed by year and quarterly. RESULTS: In the Campania region of Italy, the effects of cost containment policies, launched between 2009 and 2013, showed the prescription of biosimilars strongly increasing in 2010 until prescribing levels reached and exceeded the market share of the reference biological products in 2012. After a slight reduction, a plateau was observed at the beginning of 2013. At the same time, the use of the originator products had been decreasing until the first quarter of 2011. However, after a 1-year plateau, this trend was reversed, with a new increase in the consumption of the originators observed. CONCLUSION: Results show that the cost containment policies, applied to cut health expenditure “to cure and not to care”, did not produce the cultural change necessary to make these policies effective in the long run. Therefore, top-down policies for cost containment are not successful; rather, a bottom-up approach based on consensus among professionals should become the preferred option. |
format | Online Article Text |
id | pubmed-4646475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-46464752015-12-03 Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs Menditto, Enrica Orlando, Valentina Coretti, Silvia Putignano, Daria Fiorentino, Denise Ruggeri, Matteo Clinicoecon Outcomes Res Original Research BACKGROUND: Agency is a pervasive feature of the health care market, with doctors acting as agents for both patients and the health care system. In a context of scarce resources, doctors are required to take opportunity cost into account when prescribing treatments, while cost containment policies cannot overlook their active role in determining health care resource allocation. This paper addresses this issue, investigating the effects of cost containment measures in the market of biosimilar drugs that represent a viable and cost-saving strategy for the reduction of health care expenditure. The analysis focuses on a particular region in Italy, where several timely policies to incentivize biosimilar prescribing were launched. METHODS: Drugs were identified by the anatomical therapeutic chemical classification system. Information about biosimilar drugs and their originator biological products was extracted from the IMS Health regional database. Drug consumption was expressed in terms of counting units, while expenditure was evaluated in Euro (€). The market penetration of biosimilars was analyzed by year and quarterly. RESULTS: In the Campania region of Italy, the effects of cost containment policies, launched between 2009 and 2013, showed the prescription of biosimilars strongly increasing in 2010 until prescribing levels reached and exceeded the market share of the reference biological products in 2012. After a slight reduction, a plateau was observed at the beginning of 2013. At the same time, the use of the originator products had been decreasing until the first quarter of 2011. However, after a 1-year plateau, this trend was reversed, with a new increase in the consumption of the originators observed. CONCLUSION: Results show that the cost containment policies, applied to cut health expenditure “to cure and not to care”, did not produce the cultural change necessary to make these policies effective in the long run. Therefore, top-down policies for cost containment are not successful; rather, a bottom-up approach based on consensus among professionals should become the preferred option. Dove Medical Press 2015-11-11 /pmc/articles/PMC4646475/ /pubmed/26635482 http://dx.doi.org/10.2147/CEOR.S88531 Text en © 2015 Menditto et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Menditto, Enrica Orlando, Valentina Coretti, Silvia Putignano, Daria Fiorentino, Denise Ruggeri, Matteo Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs |
title | Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs |
title_full | Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs |
title_fullStr | Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs |
title_full_unstemmed | Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs |
title_short | Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs |
title_sort | doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646475/ https://www.ncbi.nlm.nih.gov/pubmed/26635482 http://dx.doi.org/10.2147/CEOR.S88531 |
work_keys_str_mv | AT mendittoenrica doctorscommitmentandlongtermeffectivenessforcostcontainmentpolicieslessonlearnedfrombiosimilardrugs AT orlandovalentina doctorscommitmentandlongtermeffectivenessforcostcontainmentpolicieslessonlearnedfrombiosimilardrugs AT corettisilvia doctorscommitmentandlongtermeffectivenessforcostcontainmentpolicieslessonlearnedfrombiosimilardrugs AT putignanodaria doctorscommitmentandlongtermeffectivenessforcostcontainmentpolicieslessonlearnedfrombiosimilardrugs AT fiorentinodenise doctorscommitmentandlongtermeffectivenessforcostcontainmentpolicieslessonlearnedfrombiosimilardrugs AT ruggerimatteo doctorscommitmentandlongtermeffectivenessforcostcontainmentpolicieslessonlearnedfrombiosimilardrugs |